Form 4: Rocket Pharmaceuticals Director, David P. Southwell, Reports Stock Option Grant

Director David P. Southwell reports the acquisition of stock options for 23,944 shares of Rocket Pharmaceuticals' common stock.

Summary

• David P. Southwell, a director of Rocket Pharmaceuticals, reported a transaction on June 13, 2024.
• Southwell acquired stock options for 23,944 shares of Rocket Pharmaceuticals' common stock at an exercise price of $22.86.
• These options vest fully on June 13, 2025, and expire on June 13, 2034.
• The transaction was reported on Form 4, filed with the SEC on June 20, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock option grant to a director, which is neither overwhelmingly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The size of the grant (23,944 shares) would need to be compared against grants to directors at comparable companies to determine if it is within industry norms.

Key Dates